« Return to News | Drug Sponsors | CROs/Service Providers

West Pharmaceutical signs tech agreement with Amgen

Thursday, June 21, 2012 02:42 PM

West Pharmaceutical Services, a global manufacturer of components and systems for injectable drug delivery, has signed an agreement with Amgen, an independent biotech based in Thousand Oaks, Calif., to evaluate Daikyo Crystal Zenith technologies for drug containment.

The Crystal Zenith technologies were developed over many years by West's partner, Daikyo Seiko, and are based on a polymeric container, utilizing elastomeric components with Flurotec barrier film, and provided in a sterile, validated, ready-to-fill format.

"Biopharmaceutical therapeutic products require a drug container that enables safe, effective and reliable containment," said Donald E. Morel, Jr., Ph.D., West's chairman and CEO. "We are delighted to formalize our plan to work with Amgen for evaluating the use of Daikyo Crystal Zenith in commercializing Amgen's therapeutics. We value this long-standing relationship and look forward to helping Amgen to meet its objective of advancing science and biotechnology to serve patients."

No further details of the agreement were disclosed.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.